SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

SanDisk is trending amid intense investor euphoria and a massive short squeeze, with the community actively debating whether the stock's parabolic ascentdriven by aggressive price target hikes and AI infrastructure demandis a sustainable supercycle or a speculative bubble destined for a sharp correction. Traders are locked in a fierce tug-of-war, with bulls pointing to fundamental memory storage needs while bears focus on the stock's extreme year-over-year gains and the potential for a blow-off top.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending as a major beneficiary of sector-wide capital rotation, fueled by strategic collaborations with Google and the Terafab project involving Tesla and SpaceX. The community is actively debating whether this momentum marks a sustainable turnaround for the foundry business or a temporary sentiment-driven rally.

ServiceNow, Inc. engages in the provision of an end-to-end workflow automation platform for digital businesses. Its Now Platform is a cloud-based solution embedded with artificial intelligence (AI) and machine learning (ML). The company was founded by Frederic B. Luddy in June 2004 and is headquartered in Santa Clara, CA.

ServiceNow Inc

ServiceNow is trending as it faces heavy selling pressure alongside the broader SaaS sector, driven by analyst downgrades and growing market anxiety that agentic AI models could disrupt traditional subscription-based enterprise software. Despite solid fundamentals and management's confidence, the community is deeply divided between those viewing the decline as a generational buying opportunity and those fearing a long-term structural shift away from legacy platforms.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently experiencing heightened volatility and intense community debate following a now-deleted social media post from investor Michael Burry, who suggested that Anthropic poses a significant competitive threat to the company. While bears are seizing on these comments to question Palantir's valuation and market position, many vocal supporters are dismissing the narrative as market manipulation, pointing to the company's strong fundamentals and the distinct, complementary nature of its AI operating system.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is currently at the center of a volatile discussion as investors weigh the company's aggressive 30,000-person layoff plan against its massive capital investment into AI infrastructure. While some in the community view these cost-cutting measures as a necessary pivot to fund long-term growth and stay competitive, many traders are expressing significant frustration over persistent downward price pressure and the stock's failure to maintain gains despite positive earnings and massive AI backlog figures.

Taiwan Semiconductor Manufacturing Co., Ltd. engages in the manufacture and sale of integrated circuits and wafer semiconductor devices. Its chips are used in personal computers and peripheral products, information applications, wired and wireless communications systems products, and automotive and industrial equipment including consumer electronics such as digital video compact disc player, digital television, game consoles, and digital cameras. The company was founded by Chung Mou Chang on February 21, 1987 and is headquartered in Hsinchu, Taiwan.

Taiwan Semiconductor Manufacturing - ADR

TSM is trending as record-breaking Q1 revenue and strong monthly sales confirm that AI infrastructure demand remains robust, effectively silencing concerns about a cooling cycle. The community is actively discussing the stock's role as a reliable 'lie detector' for the semiconductor industry, with investors closely watching capacity expansion and aggressive analyst price target hikes as bullish indicators despite ongoing geopolitical and supply-chain uncertainties.

Aehr Test Systems engages in the design, manufacture, market, and sale of test and burn-in equipment used in the semiconductor industry. Its products include FOX-XP, FOX-NP, and FOX-CP wafer contact parallel test and burn-in systems, the WaferPak full wafer contactor, the DiePak Carrier, the WaferPak Aligner, the DiePak Autoloader, and test fixtures. The company was founded by Rhea J. Posedel on May 25, 1977 and is headquartered in Fremont, CA.

Aehr Test Systems

Aehr Test Systems is seeing intense retail engagement and volatile price action driven by speculative optimism surrounding its role in the silicon photonics and AI hardware supercycle, despite ongoing scrutiny over its current lack of profitability and high valuation. Community sentiment remains deeply polarized between bulls betting on massive future bookings and long-term scaling, and vocal bears warning of a potential pump-and-dump setup, especially as the company continues to utilize at-the-market offerings.

Replimune Group, Inc. is a clinical-stage biotechnology company. It engages in the business of developing oncolytic immunotherapies for the treatment of cancer. The company was founded by Philip Astley-Sparke, Colin A. Love, and Robert Coffin in March 2015 and is headquartered in Woburn, MA.

Replimune Group Inc

Replimune is trending as investors react to the FDA accepting the BLA resubmission for its melanoma treatment, with a PDUFA date set for April 2026. The community is actively debating the likelihood of approval following a prior Complete Response Letter, with many analyzing whether the resubmitted data sufficiently addresses previous concerns regarding trial design and efficacy.

Back in 2011, long before “crypto Twitter”, NFTs, or VC-backed chains existed, users of the BitcoinTalk forum came up with a new currency - not to launch a network, but to make fun of btc.... and so: The first memecoin/memecurrency was born.  On May 23, 2011, a Something Awful poster cracked, “Has anyone called them buttcoins yet?”. It was sophomoric and perfect. Within weeks the gag metastasized into Buttcoin.org, a parody blog that described a “peer to peer butt” economy while cataloging mining fiascos, exchange blowups, and MLM-adjacent “innovations”.

Buttcoin

Buttcoin is gaining attention as a long-standing meme with roots dating back to 2011, now resurfacing as a community-driven project on Solana. Investors are debating its staying power compared to other meme coins, with proponents highlighting its historical lore and the potential for long-term relevance.

Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Organon & Co.

Organon & Co. is currently the subject of intense speculation as buyout rumors, particularly involving potential interest from Sun Pharma, fuel volatility alongside ongoing discussions about the company's significant debt load. While some investors are betting on a turnaround driven by the recent FDA approval for Nexplanon's extended use and VTAMA trial success, others remain cautious, debating whether the stock is a deep-value opportunity or a long-term play burdened by its balance sheet.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036)  DelveInsight

H. pylori Infections Market in the 6MM to Observe Stupendous Growth at a CAGR of 9.5% During the Forecast Period (2026-2036) | DelveInsight H. pylori Infections Market in the 6MM to Observe...

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034)  DelveInsight

Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight Biliary Tract Cancer Market is Predicted to Exhibit...

Joint U.S. Commercialization of RedHill's Talicia Commences

Joint U.S. Commercialization of RedHill's Talicia Commences Joint U.S. Commercialization of RedHill's Talicia Commences PR Newswire RALEIGH, N.C. and TEL-AVIV, Israel, Feb. 25, 2026 The full sales...

What's Going On With Redhill Biopharma Stock On Tuesday?

RedHill Biopharma shares fell after a sharp rally as investors took profits, following updates on its GI drug aimed at easing GLP-1 treatment side effects and potential FDA approval paths.read more...

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects

RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side Effects RedHill's RHB-102 Progresses in Multiple GI Indications Including GLP-1 Therapy-Related GI Side...

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells

RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells RedHill Biopharma's Positive Opaganib Results Indicate Reduction in Venetoclax Resistant Cells PR...

RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement

RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement RedHill Biopharma Successfully Regains Compliance with Nasdaq Stockholders' Equity Requirement PR...

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement

RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement RedHill Announces $10.5 Million New York Supreme Court Judgment Win Now Final for Enforcement PR Newswire...

RedHill Biopharma Receives Nasdaq Staff Determination Notification

RedHill Biopharma Receives Nasdaq Staff Determination Notification RedHill Biopharma Receives Nasdaq Staff Determination Notification PR Newswire TEL AVIV, Israel and RALEIGH, N.C., Oct. 22, 2025 On...

RedHill Biopharma’s&nbsp;stock recorded its best trading session in more than a year on Monday after the New York Supreme Court upheld a $10 million award in the company’s ongoing legal dispute with Kukbo.Shares of the company jumped 27.2%, to close at $2.34 on Monday, before slipping 7.1% to $2.17 in after-hours trading.The Court reaffirmed its original summary judgment ruling in favor of RedHill, dismissing Kukbo’s appeal and the entirety of its defense. It ruled that Kukbo breached both the subscription and exclusive license agreements signed with RedHill in 2021 and 2022 and that RedHill had properly fulfilled its obligations, even after Kukbo’s non-payment.The total award amounts to approximately $10 million,&nbsp;comprising the original judgment of $8.25 million and an additional $1.82 million granted in August 2025 for legal costs and expenses. Both awards carry a 9% ongoing statutory interest accrual. Kukbo retains the right to further appeal the ruling.In addition to the U.S. court ruling, RedHill also secured a court-ordered seizure of Kukbo’s assets in May 2025 from Korea’s Incheon District Court, freezing those assets following the initial $8.25 million award and preventing their disposal before judgment enforcement. In August, RedHill received an additional $1.82 million for legal expenses.On Stocktwits, retail sentiment was ‘extremely bullish’ amid a 9,900% surge in 24-hour message volume.One user stated that short sellers were likely to get squeezed, arguing that RedHill’s market capitalization of approximately $7 million was significantly below the $10 million court award and calling the stock undervalued, with a fair price between $5 and $7.<stembedurl>https://stocktwits.com/PeterTauscher/message/630386393</stembedurl>Another user reported an increase in their position, noting that several potential catalysts could drive the stock higher in the coming months.<stembedurl>https://stocktwits.com/Imatron12/message/630390832</stembedurl><a href="https://stocktwits.com/symbol/RDHL">RedHill Biopharma’s stock</a> has declined 62.3% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

RedHill Biopharma’s stock (RDHL) has declined 62.3% so far in 2025. (Photo credit: Getty Images)

RedHill Biopharma Logs Best Session In Over A Year After $10M Legal Victory — Retail Sees Bullish Triggers Ahead

The stock rallied after the New York Supreme Court reaffirmed RedHill’s $10 million award in its dispute with Kukbo.

Equity

RedHill Biopharma Ltd. engages in the development and commercialization of drugs for gastrointestinal (GI), infectious diseases, and oncology. The firm's products include Talicia, Movantik, and Aemcolo. It operates through the Commercial Operations and Research and Development segments. The Commercial Operations segment covers areas relating to commercial sales through a subsidiary in the United States. The Research and Development segment includes the study and licensing of therapeutic candidates. The company was founded by Dror Ben-Asher and Ori Shilo on August 3, 2009 and is headquartered in Tel Aviv, Israel.

RDHL
RedHill Biopharma Ltd.

Feed

News

Sentiment

Fundamentals

Info

Historical Earnings

Latest RDHL News

RDHLRedHill Biopharma Ltd.